LucentLucent Intel
Weekly brief·2026-11-16

CAPR, BBIO, RPRX and COGT set up a late-November FDA cluster with rare-disease approval stakes

Capricor faces a Nov. 22 FDA decision on deramiocel for Duchenne muscular dystrophy, with debate centered on how regulators weigh its cardiac data and rare-disease context. BridgeBio and Royalty Pharma both have Nov. 27 PDUFA dates, while Cogent follows on Nov. 30, creating a compact run of late-November FDA catalysts across muscle disease and other specialty indications.

Read the full brief →

Catalysts · Next 3 weeks

What’s on the calendar

$CAPRtomorrowNov 22, 2026
PDUFA·PDUFA: Deramiocel — For the Treatment of Duchenne Muscular Dystrophy
$BBIOin 6 daysNov 27, 2026
PDUFA·PDUFA: BBP-418 — Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
$RPRXin 6 daysNov 27, 2026
PDUFA·PDUFA: RPRX — target action date
$COGTin 9 daysNov 30, 2026
PDUFA·PDUFA: bezuclastinib — In patients with non-advanced systemic mastocytosis
$VRTXin 9 daysNov 30, 2026
PDUFA·PDUFA: povetacicept — IgAN
—in 14 daysDec 5, 2026
Conference·ASH Annual Meeting

Top biopharma news

Live feed

What KOLs and the press are saying

  • @Biotech2k1·The 2 biggest catalysts coming up for me are the $BBIO approval of Limb Girdle on Nov 27th and $COGT approval on Nov 30th. I don't expect any issues, but I am always cautious before big events. I keep hearing how $COGT will get a Black Box warning label. I did the research and
    6h ago
  • news$CAPR
    STAT News·STAT+: FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming
    18h ago
  • news$CAPR
    Reuters — Biopharma·Capricor's Duchenne treatment fails to get FDA approval, shares sink - Reuters
    18h ago
  • @ZacharyBrennan·$CAPR CRL for its DMD therapy after a negative adcomm (9-3 against) https://t.co/fbNrT10yb8
    18h ago
  • @adamfeuerstein·The FDA rejected $CAPR deramiocel. Finally, the Duchenne madness has stopped. Well done, FDA. https://t.co/dE6g3W5Kkx
    18h ago
  • @BiopharmIQ·FDA decisions drove the week's losers. $SMMT got a CRL (-16%), $BLTE's tinlarebant review slid to May 2027 (-16%) and $SVRA's FDA won't act by its Nov 22 PDUFA (-18%). $SLS jumped 156% on a Ph3 AML win. Next PDUFAs: $BBIO 11/27, $COGT $VRTX 11/30. 👇 https://t.co/1YOfbvS0ZF
    19h ago
  • @BiopharmIQ·FDA decisions drove the week's losers. $SMMT got a CRL (-16%), $BLTE's tinlarebant review slid to May 2027 (-16%) and $SVRA's FDA won't act by its Nov 22 PDUFA (-18%). $SLS jumped 156% on a Ph3 AML win. Next PDUFAs: $BBIO 11/27, $COGT $VRTX 11/30. 👇 https://t.co/1YOfbvS0ZF
    19h ago
  • @BiopharmIQ·FDA decisions drove the week's losers. $SMMT got a CRL (-16%), $BLTE's tinlarebant review slid to May 2027 (-16%) and $SVRA's FDA won't act by its Nov 22 PDUFA (-18%). $SLS jumped 156% on a Ph3 AML win. Next PDUFAs: $BBIO 11/27, $COGT $VRTX 11/30. 👇 https://t.co/1YOfbvS0ZF
    19h ago
  • @BPharmCatalyst·BioPharmCatalyst Weekly #Watchlist November 20, 2026: BioPharmCatalyst Weekly Watchlist: Key PDUFA left for the quarter $MLYS $COGT $PYPD $CORT $VNDA $PRAX $VTRS $VRTX $PFE $NVO Links in thread below: https://t.co/MLzxJCEwuQ
    1d ago
  • @jfais20·$COGT - one of 19 names on current DD list (shared in each Weekly Recap) GIST PDUFA in 10 days Non-Advanced SM in a month Advanced SM in late June $4.4B EV compares favorably to conservative $2.5B peak sales across indications IND applications for pan-KRAS & JAK2 V617F in Q4 https://t.co/CnyzPDT40W
    1d ago
  • news$RPRX
    Seeking Alpha — Biopharma·Royalty Pharma plc (RPRX) Presents at UBS Global Biopharma Conference 2026 Transcript - Seeking Alpha
    3d ago
  • news$VRTX
    BioSpace·Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms - BioSpace
    4d ago
  • news$COGT
    Seeking Alpha — Biopharma·Cogent Biosciences, Inc. (COGT) Presents at UBS Global Biopharma Conference 2026 Transcript - Seeking Alpha
    4d ago
  • @BiopharmIQ·More November PDUFAs ahead: $CAPR | Deramiocel, DMD | Nov 22 $BBIO | BBP-418, LGMD2I | Nov 27 $VRTX | Povetacicept, IgAN | Nov 30 Get the FREE PDUFA report: https://t.co/zbLPKM7Wlh
    5d ago
  • @BiopharmIQ·More November PDUFAs ahead: $CAPR | Deramiocel, DMD | Nov 22 $BBIO | BBP-418, LGMD2I | Nov 27 $VRTX | Povetacicept, IgAN | Nov 30 Get the FREE PDUFA report: https://t.co/zbLPKM7Wlh
    5d ago
  • @BiopharmIQ·$SMMT -10%: FDA rejected the ivonescimab BLA, wants an OS benefit (HARMONi OS p=0.057). Muted drop with AZ's $2B stake in, ~$630M cash. More PDUFAs ahead: $CAPR | Deramiocel, DMD | Nov 22 $VRTX | Povetacicept, IgAN | Nov 30 Get the FREE PDUFA report 👇 https://t.co/1YOfbvS0ZF
    5d ago
  • news$VRTX
    Seeking Alpha — Biopharma·Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript - Seeking Alpha
    5d ago
  • news$BBIO
    BioSpace·BioSpace 40 Under 40 winners Paull, Zhang let patients with rare disease lead the way at BridgeBio - BioSpace
    5d ago
  • @adamfeuerstein·@houmanhemmati No. FDA clearly communicated with $SMMT on Friday. The company chose to disclose the CRL today. I expect $CAPR to receive its CRL on Friday. It will be up to the company to disclose promptly or wait for the weekend/Monday.
    5d ago

What is Lucent

Catalyst-anchored biopharma intelligence.

Lucent is a biopharma intelligence platform. It monitors X, SEC filings, clinical trial disclosures, and analyst commentary — anchored to the catalyst calendar — and publishes a weekly synthesis.

Signal extraction

Every analyst post, FDA filing, and earnings call parsed and scored in minutes.

Catalyst calendar

1,200+ tracked events: PDUFAs, AdComs, readouts, earnings, conferences.

Cross-trial efficacy

Normalized endpoints across competing drug programs. Compare apples to apples.

Read-through alerts

Watch one ticker. Get alerted when something hits a related drug or peer.

See Lucent chat

Ask a real question. Get a cited answer.

Question
How does Rezdiffra's real-world launch trajectory compare to expectations?

Bottom line: Rezdiffra's launch appears at least in line with, and likely ahead of, prior expectations on the commercial metrics Lucent surfaces. The platform's compiled view labels execution "on track," and the freshest primary-source update available says Q1 2026 net sales reached $311.3M, with >42,250 active patients and patient count up 2.5x vs 1Q25. That is consistent with a launch that has moved beyond a cautious specialty rollout into broad physician adoption.

Why I say that

  • Lucent's Rezdiffra wiki explicitly characterizes commercial execution as strong: trailing-12-month net sales exceeded $1.1B, demand remained strong, and management framed the launch as tracking "in line with or exceeding" best-in-class specialty launches.
  • The wiki is recent — compiled 2026-06-02 — so this is not an obviously stale take.
  • The platform was thin on recent launch news/posts, so I checked the web. Madrigal's May 6, 2026 release says Rezdiffra had $311.3M Q1 2026 sales and >42,250 patients on therapy, while reiterating confidence in "robust growth expectations" for 2026.
  • An external prescription-trends paper supports the idea that uptake has been meaningful in the real world, though it covers only through Nov. 2025 and is based on pharmacy-fill data rather than full net-sales economics.

Footnotes

  1. Resmetirom — Lucent wiki (compiled 2026-06-02)

  2. Madrigal Pharmaceuticals — Q1 2026 earnings release

  3. National trends in resmetirom prescriptions for MASH — Clin Mol Hepatol

Ask ChatGPT the same question and you’ll get: Rezdiffra had a strong initial launch as the first approved MASH drug and analysts were generally positive on uptake. For specific quarterly sales figures or the latest patient counts, I'd recommend checking Madrigal's investor relations page or a recent earnings summary.

Hit rate85.7%· N=788
Tracked X accounts23
Ticker wikis125
Drug wikis140

Pilot launching this quarter

We’re inviting a small group of biopharma traders to the alpha. Tell us about your workflow and we’ll be in touch.